Ardsley Advisory Partners’s Profound Medical PROF Stock Holding History

Ardsley Advisory Partners’s Portfolio PROF Stock Details PROF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.82M	Hold	575,000	–	–	0.4%	79
2026 Q1	$3.73M	Buy	575,000 +125,000	+28%	+$863K	0.48%	64
2025 Q4	$3.54M	Buy	450,000 +120,000	+36%	+$771K	0.39%	76
2025 Q3	$1.61M	Hold	330,000	–	–	0.2%	96
2025 Q2	$1.95M	Buy	330,000 +35,000	+12%	+$185K	0.26%	87
2025 Q1	$1.72M	Hold	295,000	–	–	0.33%	87
2024 Q4	$2.22M	Buy	295,000 +20,000	+7%	+$154K	0.35%	85
2024 Q3	$2.19M	Buy	275,000 +60,000	+28%	+$542K	0.36%	73
2024 Q2	$1.8M	Buy	215,000 +70,000	+48%	+$564K	0.27%	78
2024 Q1	$1.24M	Buy	+145,000	New	+$1.21M	0.18%	85
2020 Q1	–	Sell	-10,000	Closed	-$114K	–	148
2019 Q4	$114K	Buy	+10,000	New	+$92.2K	0.02%	140

Ardsley Advisory Partners's PROF Position: Q2 2026 in Review

Ardsley Advisory Partners held its Profound Medical (PROF) position steady in Q2 2026 at 575,000 shares worth $3.82M. The position accounts for 0.4% of the portfolio, ranked #79.

Ardsley Advisory Partners first reported a position in PROF in Q4 2019 and has held it in 11 quarters since. 1 fund tracked by Wall St. Rank holds PROF as of Q2 2026.

Ardsley Advisory Partners held 575,000 shares of Profound Medical worth $3.82M as of Q2 2026.
Ardsley Advisory Partners left its Profound Medical share count unchanged in Q2 2026.
Profound Medical made up 0.4% of Ardsley Advisory Partners's portfolio in Q2 2026, its #79 holding.
Ardsley Advisory Partners first reported a position in Profound Medical in Q4 2019 and has held it in 11 quarters since.
1 fund tracked by Wall St. Rank held Profound Medical as of Q2 2026.

Based on Ardsley Advisory Partners's 13F filing for Q2 2026, filed 13 Jul 2026.